Interim Marketing Of New OTC Conditions Prohibited Under Proposed Rule
This article was originally published in The Rose Sheet
Executive Summary
Final monograph status would be required before a new OTC condition could be sold in the U.S. under FDA's proposed rule on "material time, material extent" published in the Federal Register Dec. 20. Interim marketing of conditions deemed eligible for monograph consideration would not be allowed.
You may also be interested in...
FDA “Material Time, Material Extent” May Be Cloudy For Sunscreens
Interim marketing for OTC drugs or "conditions" in the U.S. subject to a final or new monograph is barred under FDA's final rule on "material time, material extent" criteria
OCA Applauds Organic Board's Recommendation To USDA: "Outlaw Nanotech"
With a push from the Organic Consumers Association, the National Organic Standards Board is recommending that the use of nanotechnology be strictly prohibited from products certified under the National Organic Program